Autism spectrum disorders and schizophrenia spectrum disorders: Excitation/inhibition imbalance and developmental trajectories

Frontiers in Psychiatry

Volumn 8, Issue MAY, 2017, Pages

  Canitano, Roberto ^a   Pallagrosi, Mauro ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autism spectrum disorders; Children and adolescents; Excitation inhibition imbalance; Psychosis; Schizophrenia spectrum disorders

Indexed keywords

4 AMINOBUTYRIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUTAMATE DECARBOXYLASE 67; GLUTAMIC ACID; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUREXIN; NEUREXIN 1 ALPHA; NEUROLIGIN; NEUROLIGIN 1; UNCLASSIFIED DRUG;

ARTICLE; AUTISM; CHILDHOOD ONSET SCHIZOPHRENIA; CLINICAL FEATURE; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DSM-5; ERBB4 GENE; EXCITATORY TO INHIBITORY CORTICAL ACTIVITY RATIO IMBALANCE; GABAERGIC SIGNALING; GABAERGIC SYSTEM; GENE EXPRESSION REGULATION; GLUTAMATERGIC SYSTEM; HEREDITY; HUMAN; INDUCED PLURIPOTENT STEM CELL; INTERPERSONAL COMMUNICATION; MTOR SIGNALING; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROMODULATION; NRG1 GENE; PHENOTYPE; SCHIZOPHRENIA; SCHIZOPHRENIA SPECTRUM DISORDER; SIGNAL TRANSDUCTION; SOCIAL COMMUNICATION; SOCIAL INTERACTION;

EID: 85029573269     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2017.00069     Document Type: Article

References (60)

1. Hommer RE, Swedo SE. Schizophrenia and autism-related disorders. Schizophr Bull (2015) 41(2):313-4. doi:10.1093/schbul/sbu188
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association (2013).
3. Rapoport J, Chavez A, Greenstein D, Addington A, Gogtay N. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. J Am Acad Child Adolesc Psychiatry (2009) 48(1):10-8. doi:10.1097/CHI.0b013e31818b1c63
4. Driver DI, Gogtay N, Rapoport J. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am (2013) 22(4):539-55. doi:10.1016/j.chc.2013.04.001
5. King BH, Lord C. Is schizophrenia on the autism spectrum? Brain Res (2011) 1380:34-41. doi:10.1016/j.brainres.2010.11.031
6. Cochran DM, Dvir Y, Frazier JA. 'Autism-plus' spectrum disorders: intersection with psychosis and the schizophrenia spectrum. Child Adolesc Psychiatr Clin N Am (2013) 22(4):609-27. doi:10.1016/j.chc.2013.04.005
7. Marwick K, Hall J. Social cognition in schizophrenia: a review of face processing. Br Med Bull (2008) 88(1):3-58. doi:10.1093/bmb/ldn035
8. Sasson NJ, Pinkham AE, Weittenhiller LP, Faso DJ, Simpson C. Context effects on facial affect recognition in schizophrenia and autism: behavioral and eye-tracking evidence. Schizophr Bull (2016) 42(3):675-8. doi:10.1093/schbul/sbv176.3
9. de Lacy N, King BH. Revisiting the relationship between autism and schizophrenia: toward an integrated neurobiology. Annu Rev Clin Psychol (2013) 9:555-87. doi:10.1146/annurev-clinpsy-050212-185627
10. McGrath JJ, Petersen L, Agerbo E, Mors O, Mortensen PB, Pedersen CB. A comprehensive assessment of parental age and psychiatric disorders. JAMA Psychiatry (2014) 71(3):301-9. doi:10.1001/jamapsychiatry.2013.4081
11. Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol (2014) 10(11):643-60. doi:10.1038/nrneurol. 2014.187
12. Gao R, Penzes P. Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. Curr Mol Med (2015) 15(2):146-67. doi:10.2174/1566524015666150303003028
13. Chattopadhyaya B, Cristo GD. GABAergic circuit dysfunctions in neurodevelopmental disorders. Front Psychiatry (2012) 3:51. doi:10.3389/fpsyt.2012.00051
14. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience (2013) 251:90-107. doi:10.1016/j.neuroscience.2012.04.044
15. Hutsler JJ, Zhang C. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res (2010) 1309:83-94. doi:10.1016/j.brainres.2009.09.120
16. Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med (2012) 4(131):131-51. doi:10.1126/scitranslmed.3003501
17. Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S, et al. GABAB receptor agonist r-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism. Neuropsychopharmacology (2015) 40(9):2228-39. doi:10.1038/npp.2015.66
18. Spooren W, Lindemann L, Ghosh A, Santarelli L. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. Trends Pharmacol Sci (2012) 33(12):669-84. doi:10.1016/j. tips.2012.09.004
19. Reichelt AC, Rodgers RJ, Clapcote SJ. The role of neurexins in schizophrenia and autistic spectrum disorder. Neuropharmacology (2012) 62(3):1519-26. doi:10.1016/j.neuropharm.2011.01.024
20. Grayton HM, Missler M, Collier DA, Fernandes C. Altered social behaviours in neurexin 1alpha knockout mice resemble core symptoms in neurodevelopmental disorders. PLoS One (2013) 8:e67114. doi:10.1371/journal. pone.0067114
21. Di Benedetto B, Rupprecht R. Targeting glia cells: novel perspectives for the treatment of neuropsychiatric diseases. Curr Neuropharmacol (2013) 11:171-85. doi:10.2174/1570159X11311020004
22. Durieux AMS, Fernandes C, Murphy D, Labouesse MA, Giovanoli S, Meyer U, et al. Targeting glia with N-acetylcysteine modulates brain glutamate and behaviors relevant to neurodevelopmental disorders in C57BL/6J mice. Front Behav Neurosci (2015) 9:343. doi:10.3389/fnbeh.2015.00343
23. Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD. GABA(A) receptor downregulation in brains of subjects with autism. J Autism Dev Disord (2009) 39(2):223-30. doi:10.1007/s10803-008-0646-7
24. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res (2015) 161(1):4-18. doi:10.1016/j.schres.2014.03.035
25. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun (2012) 26(3):383-92. doi:10.1016/j.bbi.2011.08.007
26. Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorders: implications for interventions and therapeutics. World J Biol Psychiatry (2016) 17(3):174-86. doi:10.3109/15622975.2015.10 85597
27. Hutsler JJ, Casanova M. Review: cortical construction in autism spectrum disorder: columns, connectivity and the subplate. Neuropathol Appl Neurobiol (2016) 42(2):115-34. doi:10.1111/nan.12227
28. Opris I, Casanova MF. Prefrontal cortical minicolumn: from executive control to disrupted cognitive processing. Brain (2014) 137(7):1863-75. doi:10.1093/brain/awt359
29. Etherton MR, Tabuchi K, Harma SM, Ko J, Sudhof TC. An autism-associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor-mediated synaptic transmission in hippocampus. EMBO J (2011) 30(14):2908-19. doi:10.1038/emboj.2011.182
30. Zhang C, Milunsky JM, Newton S, Ko J, Zhao G, Maher TA, et al. A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J Neurosci (2009) 29(35):10843-54. doi:10.1523/JNEUROSCI.1248-09.2009
31. Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF, Champagne N, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet (2011) 130(4):563-73. doi:10.1007/s00439-011-0975-z
32. Kolevzon A, Angarita B, Bush L, Wang AT, Frank Y, Yang A, et al. Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring. J Neurodev Disord (2014) 6:39. doi:10.1186/1866-1955-6-39
33. Leblond CS, Nava C, Polge A, Jauthier G, Huguet G, Lumbroso S, et al. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet (2014) 10(9):e1004580. doi:10.1371/journal.pgen.1004580
34. Robertson CE, Ratai EM, Kanwisher N. Reduced GABAergic action in the autistic brain. Curr Biol (2016) 26(1):80-5. doi:10.1016/j.cub.2015.11.019
35. Oblak AL, Gibbs TT, Blatt GJ. Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem (2010) 114(5):1414-23. doi:10.1111/j.1471-4159.2010.06858.x
36. Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L, et al. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. Cell (2015) 16(162):375-90. doi:10.1016/j. cell.2015.06.034 37. Lewis DA. The chandelier neuron in schizophrenia. Dev Neurobiol (2011) 1(71):118-27. doi:10.1002/dneu.20825
37. Lewis DA. The chandelier neuron in schizophrenia. Dev Neurobiol (2011) 1(71):118-27. doi:10.1002/dneu.20825
38. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull (2008) 34(5):944-61. doi:10.1093/schbul/sbn070
39. Paoletti R, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci (2013) 14(6):383-400. doi:10.1038/nrn3504
40. Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci (2008) 8(1):6. doi:10.3389/neuro.02.006.2008
41. Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol (2016) 76:351-82. doi:10.1016/bs.apha.2016.01.006
42. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature (2014) 506(7487):179-84. doi:10.1038/nature12929
43. Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci (2013) 27(7):31. doi:10.3389/fncel.2013.00031
44. Voineagau I, Wang X, Johnston P, Tian Y, Horvath S, Mill J, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature (2011) 474(7351):380-4. doi:10.1038/nature10110
45. Tarabeux J, Kebir O, Gauthier J, Hamdan FF, Xiong L, Piton A, et al. Rare mutations in N-methyl-d-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry (2011) 15(1):e55. doi:10.1038/tp.2011.52
46. Banerjee A, Macdonald ML, Borgmann-Winter KE, Hahn CG. Neuregulin 1-erbB4 pathway in schizophrenia: from genes to an interactome. Brain Res Bull (2010) 83(3-4):132-9. doi:10.1016/j.brainresbull.2010.04.011
47. Perez-Garcia CG. ErbB4 in laminated brain structures: a neurodevelopmental approach to schizophrenia. Front Cell Neurosci (2015) 18(9):472. doi:10.3389/fncel.2015.00472
48. Mackie S, Millar JK, Porteous DJ. Role of DISC1 in neural development and schizophrenia. Curr Opin Neurobiol (2007) 17(1):95-102. doi:10.1016/j. conb.2007.01.007
49. Bradshaw NJ, DJ Porteous DJ. DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology (2012) 62(3):1230-41. doi:10.1016/j.neuropharm.2010.12.027
50. Jardri R, Hugdahl K, Hughes M, Brunelin J, Waters F, Alderson-Day B, et al. Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain? Schizophr Bull (2016) 42(5):1124-34. doi:10.1093/schbul/sbw075
51. Schneider M, Debbane M, Bassett AS, Chow EW, Fung WL, van den Bree M, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry (2014) 171(6):627-39. doi:10.1176/appi.ajp.2013.13070864
52. Zhou Y, Kaiser T, Monteiro P, Zhang X, Van der Goes MS, Wang D, et al. Mice with Shank3 mutations associated with ASD and schizophrenia display both shared and distinct defects. Neuron (2016) 89(1):147-62. doi:10.1016/j. neuron.2015.11.023
53. Sato A. mTOR, a potential target to treat autism spectrum disorder. CNS Neurol Disord Drug Targets (2016) 15(5):533-43. doi:10.2174/18715273156 66160413120638
54. Wang H, Doering LC. Reversing autism by targeting downstream mTOR signaling. Front Cell Neurosci (2013) 7:28. doi:10.3389/fncel.2013.00028
55. Gururajan A, van den Buuse M. Is the mTOR-signalling cascade disrupted in schizophrenia? J Neurochem (2014) 129(3):377-87. doi:10.1111/jnc.12622
56. Weston MC, Chen H, Swann JW. Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission. J Neurosci (2012) 32(33):11441-52. doi:10.1523/JNEUROSCI.1283-12.2012
57. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull (2009) 35(3):528-48. doi:10.1093/schbul/sbn187
58. Costa-Mattioli M, Monteggia LM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci (2013) 16(11):1537-43. doi:10.1038/nn.3546
59. Garvey M, Avenevoli S, Anderson K. The National Institute of Mental Health research domain criteria and clinical research in child and adolescent psychiatry. J Am Acad Child Adolesc Psychiatry (2016) 55(2):93-8. doi:10.1016/j. jaac.2015.11.002
60. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry (2014) 13(1):28-35. doi:10.1002/wps.20087